Targeting epigenetic regulators for cancer therapy
Susan Wee(Bristol-Myers Squibb (United States)), Liang Schweizer(HiFiBiO Therapeutics (United States)), Xiaole Shirley Liu(Dana-Farber Cancer Institute), Stephen B. Baylin(Johns Hopkins University), Robert J. Sims(Constellation Pharmaceuticals (United States)), Haitao Li(King Center), Scott A. Armstrong(Courant Institute of Mathematical Sciences), Robert A. Copeland(Epizyme (United States)), Dash Dhanak(Springhouse)
Cited by 80
Related Papers
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k
Identifying ChIP-seq enrichment using MACS
|Nature Protocols|2012|2.1k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Epigenetic Determinants of Cancer
|Cold Spring Harbor Perspectives in Biology|2016|1.3k
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
|Cancer Discovery|2016|897